Eli Lilly’s experimental weight loss drug retatrutide helped adults with obesity lose an average of 28.3% of their body weight in a late-stage trial, a result that pushes the next generation of obesity medicines closer to weight-loss levels usually associated with bariatric surgery.
The company said Thursday, May 21, that the weekly injection met the main goal of a Phase 3 study in adults with obesity or overweight who did not have diabetes but had at least one weight-related health condition. The medicine is not yet approved, but the results immediately raised expectations for a new round of competition in a market already reshaped by Wegovy, Zepbound and newer oral GLP-1 drugs.
Retatrutide Delivers Major Weight Loss In Phase 3 Trial
The most striking finding was the scale of weight reduction. Patients taking the highest tested dose of retatrutide lost an average of 28.3% of their body weight after 80 weeks. More than 45% of people on that dose lost at least 30% of their body weight.
Those numbers exceed the typical results seen with the first wave of widely used obesity injections, which have generally produced average weight loss in the mid-teens to low-20% range depending on the drug, dose, study population and duration.
Retatrutide’s performance matters because late-stage trials are the key tests used to support regulatory applications. The company has said it plans to seek approval after additional Phase 3 data are available, potentially setting up a major new obesity drug decision in 2027.
How The New Weight Loss Drug Works
Retatrutide belongs to the rapidly expanding family of metabolic medicines that grew out of diabetes treatment. It is often described as a “triple” hormone-receptor drug because it targets GLP-1, GIP and glucagon receptors.
GLP-1 drugs help reduce appetite, slow digestion and improve blood-sugar regulation. GIP is involved in insulin response and metabolism. Glucagon affects energy use and fat metabolism. By combining all three pathways, retatrutide is designed to do more than make patients feel full; it aims to alter several signals that influence body weight and metabolic health.
That broader mechanism is why the medicine has drawn intense interest. The next phase of obesity drug development is not only about producing more weight loss. Drugmakers are also trying to show benefits for related conditions such as type 2 diabetes, fatty liver disease, sleep apnea and cardiovascular risk.
Safety Questions Remain Central
The trial results also included side effects, and those details will be crucial when regulators review the medicine. Nausea, vomiting and other gastrointestinal symptoms are common across GLP-1-based treatments, especially during dose escalation.
In the highest-dose group, about 11% of patients discontinued treatment because of adverse events. A sensory side effect known as dysesthesia was also seen in 12.5% of people taking the highest dose. Dysesthesia can involve abnormal sensations such as tingling, burning or heightened skin sensitivity.
Those safety signals do not automatically block approval, but they matter because obesity medicines are often taken long term. A drug that produces very large weight loss still has to show that its risks are manageable for broad use in real-world patients, including people with multiple health conditions and those taking other medicines.
A Bigger Challenge To Wegovy And Zepbound
The obesity drug market has already changed dramatically over the past several years. Wegovy, Zepbound and related diabetes medicines have turned GLP-1 treatments into one of the most important areas in global pharmaceuticals. Demand has strained supply, changed prescribing patterns and forced insurers and governments to confront the cost of long-term treatment.
Retatrutide could raise the competitive stakes. If approved, it would give Eli Lilly another major obesity product alongside Zepbound and its oral weight loss pill. The company would be able to offer different options across injections and tablets, with retatrutide positioned as a more powerful treatment for some patients.
Novo Nordisk remains a central competitor, especially through Wegovy and its newer higher-dose and oral versions. The fight is no longer just about which company has the first major obesity drug. It is increasingly about efficacy, convenience, side effects, heart and metabolic outcomes, supply capacity and price.
Why Patients Should Be Cautious For Now
Retatrutide is promising, but it is still experimental. Patients cannot assume it is available now, and they should not seek compounded or unofficial versions of a drug that has not been approved.
The trial also does not mean one medicine will be right for everyone. Weight loss results vary, and treatment decisions depend on medical history, body mass index, related conditions, side effects, cost, insurance coverage and long-term goals. Some patients may do well on existing drugs, while others may need different dosing, combination care or surgery.
The most durable obesity care usually involves medical supervision, nutrition support, physical activity, sleep management and treatment of related conditions. Drugs can be powerful tools, but they are not simple cosmetic products.
What Comes Next
More detailed trial data will be closely watched by doctors, regulators, investors and patients. The key questions include how retatrutide performs in people with diabetes, how much weight is regained after stopping treatment, whether side effects limit use, and whether the drug improves major health outcomes beyond the number on the scale.
For now, the latest results make retatrutide one of the most closely watched new weight loss drugs in development. If later findings hold up and regulators agree that the benefits outweigh the risks, the medicine could mark the next major step in the rapidly changing treatment of obesity.
